Written Question·Department of Health and Social Care·UIN 15595
Trastuzumab Deruxtecan
Tabled: 2 July 2026
Answered: 8 July 2026
Question
Mr Adnan Hussain
Independent — Blackburn
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's severity modifier on the availability of Enhertu for patients with secondary breast cancer.
Answer
Preet Kaur GillThe National Institute for Health and Care Excellence (NICE) considered the impact of its severity modifier as part of its appraisal of Enhertu for HER2-low metastatic breast cancer. However, even with the severity weighting applied, NICE concluded that t...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 15595) →